Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jazz Pharmaceuticals PLC

124.01
-0.9900-0.79%
Volume:59.89K
Turnover:7.50M
Market Cap:7.52B
PE:-18.69
High:126.14
Open:124.91
Low:123.95
Close:125.00
52wk High:148.06
52wk Low:95.49
Shares:60.66M
Float Shares:58.65M
Volume Ratio:0.38
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.6339
EPS(LYR):9.06
ROE:-10.84%
ROA:5.19%
PB:2.03
PE(LYR):13.69

Loading ...

FDA Announces Issuance of Priority Review Voucher to Jazz Pharmaceuticals' Brain Cancer Drug Modesyo - Federal Register

THOMSON REUTERS
·
1 hour ago

Jazz Pharmaceuticals to Participate in 2025 Wells Fargo Healthcare Conference

Reuters
·
Aug 22

Jazz Pharmaceuticals Receives FDA Approval for Modeyso™ (dordaviprone), the First Treatment for Ultra-Rare Brain Tumor

Reuters
·
Aug 21

Jazz Pharmaceuticals Price Target Maintained With a $202.00/Share by Needham

Dow Jones
·
Aug 20

Jazz Pharmaceuticals and Saniona announce global license agreement

TIPRANKS
·
Aug 20

Jazz Pharmaceuticals Enters Exclusive Licensing Agreement With Saniona to Develop and Commercialize San2355

THOMSON REUTERS
·
Aug 20

Saniona- to Receive Tiered Royalties Ranging From Mid-Single Digits to Low-Double Digits on San2355 Sales

THOMSON REUTERS
·
Aug 20

Saniona Ab - Eligible for $192.5 Mln in Development & Regulatory Milestones

THOMSON REUTERS
·
Aug 20

Jazz Pharmaceuticals price target raised to $225 from $217 at BofA

TIPRANKS
·
Aug 15

1 Safe-and-Steady Stock to Target This Week and 2 We Brush Off

stock_story_highlight
·
Aug 09

Stock Track | Jazz Pharmaceuticals Soars 5.01% Following Positive Analyst Ratings and Price Target Increases

Stock Track
·
Aug 08

Jazz Pharmaceuticals Second Quarter 2025 Earnings: EPS Misses Expectations

Simply Wall St.
·
Aug 07

Deutsche Bank Adjusts Jazz Pharmaceuticals Public Price Target to $154 From $152, Maintains Buy Rating

MT Newswires Live
·
Aug 07

RBC Capital Remains a Buy on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Aug 07

Jazz Pharmaceuticals Drop in Volume Spike, Last Down 6.4% at $105.85

THOMSON REUTERS
·
Aug 07

Jazz Pharmaceuticals Secures FDA Accelerated Approval for Modeyso™ as First Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Reuters
·
Aug 07

Jazz Pharmaceuticals: Modeyso Is Expected to Be Commercially Available in Coming Weeks

THOMSON REUTERS
·
Aug 07

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

THOMSON REUTERS
·
Aug 07

Jazz Pharmaceuticals wins accelerated FDA approval of dordaviprone

TIPRANKS
·
Aug 07

Jazz Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 07